102 related articles for article (PubMed ID: 9889036)
1. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors.
McCluskey LL; Chen C; Delgadillo E; Felix JC; Muderspach LI; Dubeau L
Gynecol Oncol; 1999 Jan; 72(1):87-92. PubMed ID: 9889036
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
3. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
[TBL] [Abstract][Full Text] [Related]
4. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
[TBL] [Abstract][Full Text] [Related]
5. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas.
Datar RH; Naritoku WY; Li P; Tsao-Wei D; Groshen S; Taylor CR; Imam SA
Gynecol Oncol; 1999 Sep; 74(3):338-45. PubMed ID: 10479490
[TBL] [Abstract][Full Text] [Related]
6. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
[TBL] [Abstract][Full Text] [Related]
7. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
8. Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases.
Luo MP; Gomperts B; Imren S; DeClerck YA; Ito M; Velicescu M; Felix JC; Dubeau L
Gynecol Oncol; 1997 Dec; 67(3):277-84. PubMed ID: 9441775
[TBL] [Abstract][Full Text] [Related]
9. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
Zheng W; Luo MP; Welt C; Lambert-Messerlian G; Sung CJ; Zhang Z; Ying SY; Schneyer AL; Lauchlan SC; Felix JC
Gynecol Oncol; 1998 Apr; 69(1):23-31. PubMed ID: 9570994
[TBL] [Abstract][Full Text] [Related]
10. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
11. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827
[TBL] [Abstract][Full Text] [Related]
12. Telomerase activity in benign and malignant epithelial ovarian tumors.
Wan M; Li WZ; Duggan BD; Felix JC; Zhao Y; Dubeau L
J Natl Cancer Inst; 1997 Mar; 89(6):437-41. PubMed ID: 9091645
[TBL] [Abstract][Full Text] [Related]
13. In situ analysis of p16/INK4 promoter hypermethylation in esophageal carcinoma and gastric carcinoma.
Zhang F; Wang L; Wu PP; Yan ZW; Zheng L; Yu YY; Jiang XC
Chin J Dig Dis; 2004; 5(4):149-55. PubMed ID: 15612883
[TBL] [Abstract][Full Text] [Related]
14. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
15. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma.
Bhagat R; Kumar SS; Vaderhobli S; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2014 Sep; 35(9):9069-78. PubMed ID: 24913706
[TBL] [Abstract][Full Text] [Related]
17. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
Hasegawa M; Nelson HH; Peters E; Ringstrom E; Posner M; Kelsey KT
Oncogene; 2002 Jun; 21(27):4231-6. PubMed ID: 12082610
[TBL] [Abstract][Full Text] [Related]
18. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer.
Goto T; Mizukami H; Shirahata A; Sakata M; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y; Hibi K
Anticancer Res; 2009 Jan; 29(1):275-7. PubMed ID: 19331161
[TBL] [Abstract][Full Text] [Related]
20. Retinoblastoma protein expression in ovarian epithelial neoplasms.
Niemann TH; Trgovac TL; McGaughy VR; Lewandowski GS; Copeland LJ
Gynecol Oncol; 1998 Jun; 69(3):214-9. PubMed ID: 9648590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]